1. Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 2003;160:1233-41.
2. Bush G, Fink M, Petrides G, et al. Catatonia I: Rating scale and standardized examination. Acta Psychiatr Scand 1996;93:129-36.
3. Northoff G. What catatonia can tell us about “top-down” modulation:” a neuropsychiatric hypothesis. Brain Behav Sci 2002;25:555-604.
4. Carroll BT. The universal field hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectrums 2000;5(7):26-33.
5. Carroll BT. Catatonia is the rosetta stone of psychosis (poster presentation). New York: American Psychiatric Association annual meeting, 2004.
6. Barnes MP, Saunders M, Walls TJ, et al. The syndrome of Karl Ludwig Kahlbaum. J Neurol Neurosurg Psychiatry 1986;49:991-6.
7. Carroll BT, Anfinson TJ, Kennedy JC, et al. Catatonic disorder due to general medical conditions. J Neuropsychiatry Clin Neurosci 1994;6:122-33.
8. Hawkins JM, Archer KJ, Strakowski SM, Keck PE. Somatic treatments of catatonia. Int J Psychiatry Med 1995;25:345-69.
9. Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 1990;51:357-62.
10. Dose M. Neuroleptic-induced pseudo-catatonia. Pharmacopsychiatry 2001;34:262-4.
11. Keck PE, Jr, Pope HG, Jr, Cohen BM, et al. Risk factors for neuroleptic malignant syndrome. Arch Gen Psychiatry 1989;46:914-18.
12. White DAC. 17 catatonic patients diagnosed as neuroleptic malignant syndrome. CNS Spectrums 2000;5:58-65.
13. Levy WO, Nunez CY. Use of ziprasidone to treat bipolar-associated catatonia. Bipolar Disord 2004;6:166-7.
14. Hesslinger B, Walden J, Normann C. Acute and long-term treatment of catatonia with risperidone. Pharmacopsychiatry 2001;34:25-6.
15. Kruger S, Braunig P. Intravenous valproic acid in the treatment of severe catatonia. J Neuropsychiatry Clin Neurosci 2001;13:303-4.
16. Kritzinger PR, Jordaan GP. Catatonia: an open prospective series with carbamazepine. Int J Neuropsychopharmacol 2001;4:251-7.
17. Northoff G, Eckert J, Fritze J. Glutamatergic dysfunction in catatonia? Successful treatment of three acute akinetic catatonic patients with the NMDA antagonist amantadine. J Neurol Neurosurg Psychiatry 1997;62:404-6.
18. Namenda (memantine) Package labeling. Forest Laboratories, 2004.
19. Ungvari GS, Chie HFK, Chow LY, et al. Lorazepam for chronic catatonia: a random, double-blind, placebo-controlled, cross-over study. Psychopharmacol 1999;142:393-8.
20. Mobius HJ. Pharmacologic rationale for memantine in chronic cerebral hypoperfusion, especially vascular dementia. Alz Dis Assoc Disord 1999;13(suppl 3):172-8.
